Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
Ultragenyx Pharmaceutical profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Ultragenyx Pharmaceutical's profit margin for the twelve months ending Jun 30, 2026 was -81.7%. For fiscal 2025 it was -85.4%, against -101.6% the year before. The highest annual figure on record is -68.8% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -85.4% | +16.2 |
| FY2024 | Dec 31, 2024 | -101.6% | +38.3 |
| FY2023 | Dec 31, 2023 | -139.9% | +54.8 |
| FY2022 | Dec 31, 2022 | -194.7% | −65.5 |
| FY2021 | Dec 31, 2021 | -129.2% | −60.4 |
| FY2020 | Dec 31, 2020 | -68.8% | +319.5 |
| FY2019 | Dec 31, 2019 | -388.3% | −4.6 |
| FY2018 | Dec 31, 2018 | -383.7% | +11183.6 |
| FY2017 | Dec 31, 2017 | -11567.3% | +173300.3 |
| FY2016 | Dec 31, 2016 | -184867.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -43.0% | +25.9 |
| Q1 FY2026 | Mar 31, 2026 | -136.0% | −27.4 |
| Q4 FY2025 | Dec 31, 2025 | -62.0% | +18.9 |
| Q3 FY2025 | Sep 30, 2025 | -112.8% | −17.1 |
| Q2 FY2025 | Jun 30, 2025 | -68.9% | +20.6 |
| Q1 FY2025 | Mar 31, 2025 | -108.6% | +48.2 |
| Q4 FY2024 | Dec 31, 2024 | -80.9% | +16.3 |
| Q3 FY2024 | Sep 30, 2024 | -95.7% | +67.1 |
| Q2 FY2024 | Jun 30, 2024 | -89.5% | +58.1 |
| Q1 FY2024 | Mar 31, 2024 | -156.8% | +6.3 |
| Q4 FY2023 | Dec 31, 2023 | -97.2% | +49.7 |
| Q3 FY2023 | Sep 30, 2023 | -162.8% | +107.4 |
| Q2 FY2023 | Jun 30, 2023 | -147.6% | +29.5 |
| Q1 FY2023 | Mar 31, 2023 | -163.2% | +27.4 |
| Q4 FY2022 | Dec 31, 2022 | -146.9% | −0.1 |
| Q3 FY2022 | Sep 30, 2022 | -270.2% | −180.8 |
| Q2 FY2022 | Jun 30, 2022 | -177.0% | −36.3 |
| Q1 FY2022 | Mar 31, 2022 | -190.6% | −53.6 |
| Q4 FY2021 | Dec 31, 2021 | -146.9% | −120.6 |
| Q3 FY2021 | Sep 30, 2021 | -89.4% | −4.9 |
| Q2 FY2021 | Jun 30, 2021 | -140.8% | −181.8 |
| Q1 FY2021 | Mar 31, 2021 | -137.0% | +190.8 |
| Q4 FY2020 | Dec 31, 2020 | -26.2% | +237.3 |
| Q3 FY2020 | Sep 30, 2020 | -84.5% | +353.5 |
| Q2 FY2020 | Jun 30, 2020 | 41.0% | +451.7 |
| Q1 FY2020 | Mar 31, 2020 | -327.8% | +204.6 |
| Q4 FY2019 | Dec 31, 2019 | -263.5% | +276.6 |
| Q3 FY2019 | Sep 30, 2019 | -438.0% | +304.3 |
| Q2 FY2019 | Jun 30, 2019 | -410.7% | +1.5 |
| Q1 FY2019 | Mar 31, 2019 | -532.4% | −815.8 |
| Q4 FY2018 | Dec 31, 2018 | -540.1% | +2845.6 |
| Q3 FY2018 | Sep 30, 2018 | -742.2% | +39271.4 |
| Q2 FY2018 | Jun 30, 2018 | -412.1% | +1425327.9 |
| Q1 FY2018 | Mar 31, 2018 | 283.3% | +58758.1 |
| Q4 FY2017 | Dec 31, 2017 | -3385.7% | – |
| Q3 FY2017 | Sep 30, 2017 | -40013.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -1425740.0% | – |
| Q3 FY2016 | Sep 30, 2016 | -58474.8% | – |
See a number that looks wrong?